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Abstract
Genes, short-hairpin RNA (shRNA), small-interfering RNA (siRNA), and decoy DNA 
can be principally used as tools for the treatment and prevention of many disorders, 
including but not limited to cancers, genetic disorders, and inherited diseases. This is 
accomplished by introducing exogenous nucleic acids into mammalian cells to modulate 
gene expression. However, direct use of such oligonucleotide drugs is hampered by sev-
eral barriers, including their degradation by nucleases present in the blood and extracel-
lular fluid, cell-membrane impermeability, and their retention in endosomes. To address 
this issue, the development of safe and effective delivery vectors has emerged as the 
main fundamental challenge for successful gene and oligonucleotide therapy. Due to the 
intrinsic risks associated with viral vectors, non-viral vectors have attracted increasing 
attention as gene and oligonucleotide carriers. We originally developed various cyclodex-
trin (CyD) conjugates with polyamidoamine (PAMAM) dendrimers as novel CyD-based 
polymers for the delivery of plasmid DNA, siRNA, shRNA, and decoy DNA. In this 
review, we describe the recent findings on PAMAM dendrimer conjugates using CyDs as 
carriers for gene, shRNA, siRNA, and decoy DNA delivery.
Keywords: cyclodextrin, polyamidoamine dendrimer, conjugate, DNA delivery, shRNA 
delivery, siRNA delivery
1. Introduction
The principle of somatic gene therapy is to introduce certain genes into selected cells to treat a 
genetic or acquired disease by interfering with the expression of specific proteins or potentially 
fixing a genetic mutation. Since the discovery of gene therapy, new perspectives for diagnosis, 
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prevention, and treatment of incurable diseases have evolved, including those related to various 
types of cancers, cardiovascular diseases, dermatological diseases, and even vision loss [1–3]. 
Successful gene therapy requires a delivery system capable of efficiently delivering the genetic 
cargo to all target cells. There are two different technologies that have been developed for this 
purpose: (1) viral and two types of non-viral vectors, and (2) lipofection and polyfection. As of 
2012, >1800 clinical trials have been performed in >31 countries [4], with lipofection and naked 
DNA representing only 6.2 and 18.6% of the methods studied, respectively. However, polyfec-
tion has never been applied to such clinical trials. Notably, in July 2012, the European Medicines 
Agency recommended Glybera, which is a gene-therapy product based on an engineered adeno-
associated viral vector for the treatment of severe lipoprotein-lipase deficiency in muscles, for 
approval as the first gene-therapy drug in the European Union. More recently, Strimvelis was 
approved by the European Commission in 2016 as the first ex vivo stem cell gene therapy for the 
treatment of patients with a very rare disorder called severe combined immunodeficiency due 
to adenosine deaminase deficiency. In some cases, viral vectors have the advantage of produc-
ing higher gene expression, although there are potential safety risks, such as immunogenicity 
that causes inflammatory reactions, toxin production, oncogenesis, and insertional mutagen-
esis [5]. The advantages of non-viral vectors in this context include higher safety levels, lower 
immunogenicity, cost-effectiveness, and their ability to attach a targeting ligand [6]. However, 
the efficiency of non-viral systems for gene delivery is markedly low in regard to gene transduc-
tion as compared with viral vectors, likely due to the lack of recognition receptors and lower 
endosomal-escape capability and nuclear-pore targeting [7]. Therefore, non-viral vectors have 
been continuously researched and developed in order to overcome their disadvantages and suc-
cessfully achieve the desired effects of gene therapy.
The discovery of RNA interference (RNAi) as an endogenous tool capable of fine-tuning gene 
expression is considered as one of the most important discoveries in the recent years [8]. 
Since then, many efforts have been made to exploit this natural mechanism to experimentally 
silence target genes, as well as to study functional genomics by inhibiting gene expression via 
the degradation of specific mRNA. Selective gene silencing by RNAi can be achieved either 
by cytoplasmic delivery of double-stranded small-interfering RNA (siRNA; 21–27 bp) or by 
nuclear delivery of gene-expression cassettes that express short-hairpin RNA (shRNA) [9, 10].
There are many types of nucleic acid drugs, including siRNA, microRNA (miRNA), anti-
sense oligonucleotides, decoy DNA, aptamers, and ribozymes. siRNA is a double-stranded 
RNA that targets specific mRNA harboring a complementary sequence and causes its deg-
radation; whereas, miRNA is a small noncoding-RNA molecule found in plants and ani-
mals and exhibiting functions related to RNA silencing and posttranscriptional regulation 
of gene expression. Furthermore, antisense oligonucleotides are single-stranded DNA har-
boring a complementary sequence with that of RNA molecules used to inhibit its expres-
sion. Decoy DNAs are short double-stranded oligodeoxynucleotides containing the binding 
sequence of a transcription factor, which prevents the transcription factor from binding to the 
genomic promoter, thereby resulting in transcription inhibition. Additionally, an aptamer is a 
nucleic acid molecule (DNA or RNA) that binds to targets with high selectivity and sensitiv-
ity, whereas ribozymes are RNA enzymes capable of binding to specific RNA, resulting in 
sequence-specific cleavage. Considering the marketed nucleic acid drugs, we can find only 
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two antisense products and one aptamer product. Vitravene (fomivirsen) is the first mar-
keted antisense product approved by the Food and Drug Administration, and represents an 
antiviral antisense drug used for the treatment of patients with cytomegalovirus retinitis or 
those with acquired immune deficiency syndrome. The second antisense product is Kynamro 
(mipomersen sodium), which is used to treat patients with homozygous familial hypercholes-
terolemia. The aptamer product is Macugen (pegaptanib sodium), which is an anti-angiogenic 
drug used for the treatment of age-related macular degeneration and that binds specifically to 
vascular endothelial growth factor protein to block its activity. However, there are currently 
no commercially marketed or approved decoy DNA or siRNA drugs, although several siRNA 
and miRNA drugs have been in clinical trials [11].
The direct use of such nucleic acid drugs has been hindered by multiple barriers that prevent 
these genes and nucleic acids from reaching their targets. These barriers include degradation 
of nucleic acids by nucleases in the blood and extracellular fluid, elimination by the reticulo-
endothelial system, cell-membrane impermeability, and their retention and in endosomes and 
subsequent degradation [12]. Consequently, the development of a delivery system capable of 
overcoming these barriers is extremely important to achieving the required effects of these 
nucleic acid drugs. Non-viral vectors have been developed for this purpose due to their higher 
safety levels, non-immunogenicity, and non-pathogenicity. Methods using non-viral carriers 
include lipofection, which depends upon liposomes to deliver the nucleic acid cargo, polyfec-
tion, which is based on the use of a polycation complex with nucleic acids, and lipopolyfection.
Polycation-based nucleic acid drug-delivery methods offer adequate efficiency in protecting the 
therapeutic genes against the aforementioned barriers and also help in overcoming intracellu-
lar barriers [13]. One of the most promising approaches to non-viral delivery of nucleic acids 
and genes involves cationic polymers due to their ease of manufacture, flexible properties, and 
robustness [14]. Polyamidoamine (PAMAM) Starburst dendrimers (dendrimers), which were 
developed by Tomalia et al., represent the first polycations exhibiting intrinsic endosomal-release 
activity, thereby removing the need to add external endosomolytic agents as required by other 
polycations, such as poly(L-lysine) [15–17]. The dendrimers are biocompatible, non-immuno-
genic, and water-soluble polymers possessing unique, spherical, and highly ordered structures 
with a narrow molecular-weight distribution, very low polydipersity, and specific size [18, 19].
These characteristics attracted many nanotechnology, pharmaceutical, and medicinal chemis-
try scientists interested in their use for various applications. Because, dendrimers have termi-
nal modifiable amino-functional groups positively charged at physiological pH [20], and they 
are capable of forming complexes with genes [15, 21] and oligonucleotides [22] through elec-
trostatic interactions, as well as with glycosaminoglycans on cell surfaces [23]. Furthermore, 
their proton-sponge effect, as well their defined shapes, explains their high degree of trans-
fection efficiency. In this case, the proton-sponge effect is produced by the large buffering 
capacity of cationic polymers that stimulate endosome swelling and eventual endosomal-
membrane disruption and release of nucleic acid drugs into the cytosol [24]. The ability of 
dendrimers to act as non-viral vectors depends greatly upon their number of generations, 
with the gene-transfer activity of dendrimers with a high number of generations exceeding 
that of those with a low number of generations, although their cytotoxicity increases as the 
number of generations increases [25, 26]. Consequently, there has been growing interest in 
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developing modified dendrimers possessing high levels of safety along with low numbers of 
generations due to their extremely low cytotoxicity [27–29].
The potential use of cyclodextrins (CyDs) as carriers of nucleic acids based of their direct inter-
action would not be expected, given that they exhibit very weak interactions with nucleic acids 
[30]. Therefore, combining CyDs with cell-penetrating nucleic acid carriers (cationic polymers) 
or modifying the CyD structure was necessary for their internalization. Various methods have 
been adopted to enhance the interactions between CyD polymers and conjugates with nucleic 
Figure 1. PAMAM dendrimer conjugates with various CyD (CDEs) and targeting ligands. GUG-β-CyD, glucuronylglucosyl-
β-CyD; Man-α-CDE, mannosylated-CDE; Gal-α-CDE, galactosylated-CDE; Fol-PαC, folate-PEG-appended α-CDE; 
Man-S-α-CDE, mannosyloxypropylthioalkylated-α-CDE; Fuc-S-α-CDE, fucosyloxypropylthioalkylated-α-CDE; Lac-
α-CDE, lactosylated-CDE; PEG-LαC, PEGylated Lac-α-CDE; Lac-PαC, lactose-PEG-appended α-CDE; PAMAM, 
polyamidoamine.
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acids [31]. Davis et al. modified the β-CyD structure to form a bifunctionalized β-CyD with 
two amine groups, allowing its incorporation into the backbone of other linear polymers [32]. 
The new polymer, CALAA-01, was ultimately established as the first targeted delivery mecha-
nism of synthetic siRNA in humans for the treatment of solid tumors [33]. However, various 
CyD-containing polymers used as nucleic acid vectors have also been reported [34, 35]. In this 
regard, Arima and Motoyama originally developed various CyD conjugates with dendrimers 
as CyD-based polymers for the delivery of various nucleic acid drugs (Figure 1).
2. Polyamidoamine (PAMAM) dendrimer conjugates with α-CyDs 
(α-CDEs) as nucleic acid carriers
2.1. α-CDEs as plasmid (p) DNA carriers
Arima et al. prepared a variety of CyD conjugates with PAMAM dendrimers (CDE) and uti-
lized them as gene and nucleic acid drug carriers. Originally, Arima et al. prepared dendrimer 
[generation 2 (G2)] conjugates with α-, β-, and γ-CyDs and named them α-, β-, and γ-CDEs 
(G2), respectively [36]. Among these CDEs, α-CDE (G2) exhibited the most prominent gene-
transfer activity, showing 100-fold higher luciferase gene-transfer activity as compared with 
that of dendrimer (G2) alone or its physical mixture with α-CyD in NIH3T3 cells, a mouse 
embryo fibroblast cell line, and RAW264.7 cells, a mouse macrophage-like cell line. This was 
attributed not only to increased levels of cellular association, but also to the augmented endo-
somal-escape ability of the pDNA complex due to the synergy of both the proton-sponge 
effect and the ability of α-CyD to disrupt the endosomal membrane. Afterward, Kihara et al. 
examined the optimal dendrimer generation (G2, G3, or G4) and degree of substitution (DS) 
for α-CyD in the α-CDE molecule [37]. Consequently, α-CDE (G3, DS2) showed the highest 
transfection efficiency along with low cytotoxicity, which was superior to that of TransFact 
and Lipofectin when tested in NIH3T3 cells. Furthermore, to elucidate the reason behind 
the superior gene-transfer activity of α-CDE (G3, DS2), Arima et al. investigated the cellular 
uptake, intracellular distribution, and the physicochemical properties of pDNA complexes 
involving both α-CDE (G3, DS2) and the dendrimer (G3). The particle sizes, as well as the 
ζ-potential values, were nearly the same for both complexes. Furthermore, the enhanced 
gene-transfer activity could not be explained based on cellular uptake, as the values of the 
complexes with α-CDEs (G2, G3, and G4) were equivalent to those observed with their parent 
dendrimers, suggesting that factors other than cellular uptake or the physicochemical proper-
ties of the α-CDE (G3, DS2)/pDNA complexes might be strongly associated with improving 
gene-transfer activity. To elucidate the mechanism of cellular uptake, Arima et al. studied the 
effect of different endocytosis inhibitors on the cellular uptake of fluorescein isothiocyanate-
labeled pDNA [(FITC)-pDNA] complexes with tetramethylrhodamine-5-(and 6)-isothiocy-
anate-labeled α-CDE [TRITC-α-CDE (G3)] transfection in A549 cells, ultimately using flow 
cytometry and confocal laser-scanning microscopy (CLSM) to observe the colocalization of 
TRITC-α-CDE (G3), FITC-endocytosis markers, and FITC-pDNA after transfection.
Consequently, after transfection of pDNA complexes, the complexes with TRITC-α-CDE 
(G3, DS2) colocalized with the endocytosis markers FITC-transferrin and FITC-cholera toxin 
B. Similarly, the gene-transfer activity of α-CDE (G3, DS2) was markedly lowered by the addition 
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of clathrin-dependent endocytosis inhibitors (i.e., chlorpromazine and sucrose) and raft-depen-
dent endocytosis inhibitors (i.e., nystatin and filipin), but not by amiloride, the macropinocy-
tosis inhibitor. These results suggested that the main mechanism of α-CDE (G3, DS2) uptake 
involved clathrin- and raft-dependent endocytosis. To confirm the release of the complex from 
endosomes, we observed the intracellular distribution of the α-CDE (G3, DS2)/FITC-pDNA com-
plex by CLSM, finding that the green fluorescence originating from FITC-pDNA in the case of 
the α-CDE (G3, DS2) complex was predominantly localized in the cytoplasm to a much greater 
degree than that of the dendrimer system, confirming the improved capability for endosomal dis-
ruption conferred by the synergy between α-CDE and the proton-sponge effect of the dendrimer.
Moreover, in vivo studies of α-CDE (G3, DS2), as well as dendrimer complexes with pDNA, 
were evaluated after intravenous administration of 50 μg pDNA/mouse at a charge ratio of 
10. After 12 h, organs were collected, and pDNA levels in various organs were determined. 
The results showed that α-CDE (G3, DS2) delivered pDNA more efficiently in the liver and 
kidney; however, the highest gene-expression levels were observed in the spleen. Blood-
chemistry data related to α-CDE administration, including aspartate aminotransferase (AST), 
lactate dehydrogenase (LDH), blood urea nitrogen (BUN), alanine aminotransferase (ALT), 
and creatinine (CRE) concentrations, showed minor changes as compared with those asso-
ciated with the dendrimer [38]. These results suggested potential use of α-CDE (G3, DS2) 
as a safe and promising non-viral pDNA vector, although additional modifications of the 
α-CDE (G3, DS2) chemical structure were required to improve its nuclear translocation enable 
improved gene-expression results [39].
2.2. α-CDE (G3) as siRNA carriers
Assessment of the siRNA-carrier ability of α-CDE (G3, DS2) was performed by Tsutsumi et al. 
using a luciferase-reporter system [40, 41]. Their results showed significant reductions in the 
luciferase activity of the α-CDE (G3, DS2) system as compared with that observed in the con-
trol and accompanied by negligible cytotoxicity after transfection with the ternary complex 
pDNA/siRNA/α-CDE (G3, DS2). In this study, α-CDE (G3, DS2) showed superior transfec-
tion efficiency relative to that of the dendrimer and other commercially available transfection 
reagents. Additionally, they observed that the complex localized exclusively to the cytoplasm, 
where RNAi-related activity occurs, and as a result of the lack of a nuclear-translocation 
moiety in α-CDE (G3, DS2). Tsutsumi et al. also reported efficient knockdown of the fire-
fly luciferase gene using a α-CDE (G3, DS2)/siRNA binary system accompanied by negli-
gible cytotoxicity as compared with the use of siRNA complexes with commercially available 
transfection reagent (Lipofectamine 2000 and RNAiFect). Furthermore, the physicochemical 
properties, local irritation, cytotoxicity, interferon response, cellular uptake, and intracellular 
distribution of the siRNA complexes, as well as the RNAi activity associated with the α-CDE 
(G3, DS2)/siRNA complex, were evaluated on endogenous gene-expression in Colon-26-luc 
and NIH3T3-luc cells stably expressing the pGL3 luciferase gene. The results revealed potent 
RNAi activity against Lamin A/C and Fas expression along with minor cytotoxicity as com-
pared with commercial transfection agents [40]. Additionally, siRNA complexed with α-CDE 
(G3, DS2) was protected from degradation by serum nucleases. Intriguingly and somewhat 
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similar to results observed with the α-CDE (G3, DS2)/pDNA complex, α-CDE (G3, DS2)/FITC-
siRNA was delivered exclusively to the cytoplasm in NIH3T3-luc cells. Additionally, when 
this system was applied in vivo in mice bearing Colon-26-luc tumors, α-CDE (G3, DS2)/siGL3 
(siRNA against pGL3 gene) showed potent RNAi activity against pGL3 expression after intra-
venous, as well as intratumoral, injection. Moreover, the siRNA complex neither triggered 
the immune response nor changed blood-chemistry data, indicating its safety. These results 
suggested the potential of α-CDE (G3, DS2) as a novel siRNA-carrier candidate for both in 
vivo and in vitro applications.
2.3. α-CDE (G3) as shRNA carriers
To improve upon and prolong the duration of RNAi-mediated gene knockdown, vector-
based shRNA-expression systems were developed [42]. Upon shRNA transfection into mam-
malian cells, the insert containing the vector is transferred to the nucleus, integrated into 
the host genome, expressed, and quickly processed by Dicer-dependent cleavage and loaded 
into the RNA-induced silencing complex, which is then directed to the target mRNA, result-
ing in its degradation. A previous study demonstrated the potential of α-CDE (G3, DS2) 
as a novel carrier of pDNA expressing shRNA [43]. In this study, the authors used pDNA 
expressing shRNA against the pGL3 firefly luciferase gene (shGL3). Even at a low charge 
ratio, α-CDE (G3, DS2) capably formed a stable condensed complex with shGL3 and induced 
the conformational transition of shRNA in solution from B-form to the more compact C-form 
DNA. Furthermore, α-CDE (G3, DS2) markedly inhibited shGL3 degradation by DNase I, and 
the α-CDE (G3, DS2)/shGL3 complex showed the most potent RNAi activity at a charge ratio 
of 20 along with negligible cytotoxicity and without off-target effects in A549 cells, a human 
alveolar adenocarcinoma cell line, while also transiently expressing the luciferase gene in 
NIH3T3-luc cells. Moreover, the addition of sufficient amounts of siGL3 along with α-CDE 
(G3, DS2)/shGL3 dramatically enhanced the RNAi activity, which was ascribed to the stabi-
lizing effect of α-CDE (G3, DS2) against DNase I degradation of the shRNA accompanied by 
negligible cytotoxicity. These results suggested that α-CDE (G3, DS2) possessed the potential 
to be a novel shRNA carrier.
2.4. Functionalized α-CDEs as cell-specific DNA and siRNA carriers
In the early 1900s, the German Noble laureate Paul Ehrlich first introduced the concept of 
targeted drug delivery [44, 45]. At that time, he called it the “magic bullet”, as it was able to 
deliver the drug specifically to microbes (such as bacteria) without harming the body. His 
continuous research eventually led to the development of the first effective drug against syph-
ilis (Salvarsan). The primary aim of targeted drug-delivery systems is to increase the concen-
tration of the medication in specific areas of the body relative to others, thereby improving 
its therapeutic index and reducing cytotoxicity. Various approaches have been adopted to 
target medications to the disease site [46, 47] with many compounds internalized inside of 
cells via receptor-mediated endocytosis. Receptor-mediated techniques use ligands attached 
to polyplexes to transfect cells with selected genes. Endocytosis is then mediated by various 
receptors, such as asialoglycoprotein receptor (ASGPR), mannose receptor (ManR), fucose 
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receptor (FucR), and folate receptor (FR). However, despite the advantages offered by such 
systems, some drawbacks exist, including immune reactions against the carriers and rapid 
disposition of the carriers, as well as redistribution of the drugs after their release from the 
carriers [48]. Therefore, Arima et al. focused on how to improve CDEs for efficient delivery of 
gene and nucleic acid drugs to various organs through the attachment of various ligands to 
existing CDEs to aid the process of receptor-mediated endocytosis.
2.4.1. Galactosylated α-CDE as a hepatocyte-selective pDNA carrier
The liver consists mainly of hepatocytes (nearly 70%) and parenchymal cells. Gene- or drug-
targeting systems designed to target the liver are usually directed to hepatocytes, which 
overexpress ASGPRs on their cell surface. These ASGPRs mediate the removal of poten-
tially hazardous glycoconjugates from the blood; therefore, ASGPRs are usually targeted 
using galactose residues coupled with a core molecule to enhance binding [49, 50]. Many 
approaches, including but not limited to (1) intravenous injection of pDNA within liposomes 
[51, 52] or via ASGPR targeting [53] and (2) intra-portal injection of recombinant adenovirus 
[54] and retroviral vectors [55] have been adopted to deliver foreign genes in vivo to hepato-
cytes. Moreover, an in vitro system that takes advantage of ASGPR-mediated endocytosis to 
transfect hepatocytes with an exogenous DNA using a soluble DNA carrier was developed 
[56]. Various ASGPR-mediated gene-delivery systems using different polymers have also 
been described, including galactose-polyethylene glycol (PEG)-poly(L-lysine) [57], galacto-
sylated PEG-graft-polyethylenimine (PEI) [58, 59], and galactosylated chitosan-grafted-PEI 
[60]. In order to attain hepatocyte-specificity and/or improve the efficacy of α-CDE as a gene-
delivery carrier, Arima et al. attached a galactose residue to form Gal-α-CDE (G2) as a novel 
non-viral carrier [61]. The galactose moieties were attached to the primary amino groups 
of α-CDE (G2) through a spacer consisting of α-D-galctopyranosylphenyl isothiocyanate, 
achieving various degrees of substitutions of galactose (DSGs; 1, 4, 5, 8, and 15). Evaluation 
of the complexation ability of the pDNA complexes by electrophoresis showed that the Gal-
α-CDEs (G2) could form complexes with pDNA; however, complexation ability decreased 
along with increasing DSG values, possibly due to decreases in free positive-charged primary 
amino groups. Moreover, the ability of these carriers to protect the pDNA from degradation 
by serum nucleases also decreased along with increasing DSGs, likely due to the attenuated 
interactions and loss of pDNA-condensation ability in the presence of high DSGs in the con-
jugates. Additionally, they observed that Gal-α-CDEs (G2, DSG4) elicited the most prominent 
gene-transfer activity relative to that of the dendrimer (G2), and α-CDE (G2, DS2) in HepG2 
cells, a human hepatoma cell line, NIH3T3 cells, and A549 cells showed no cytotoxicity up to 
a charge ratio of 200. Surprisingly, this was independent of ASGPR expression, possibly due 
to the inability of the spacer to properly present the galactose residue for receptor recogni-
tion. Therefore, these results suggested the potential of Gal-α-CDE (G2, DSG4) as a novel 
non-viral vector independent of cell-surface ASGPR expression. It is worth mentioning that 
in this study, the authors used a cancer-cell line (HepG2) and not normal hepatocytes, given 
that they both express ASGPR at similar levels, and HepG2 cells are widely used by scientists 
engaged in targeting studies for genes using non-viral carriers. Surprisingly, the addition of 
10% fetal bovine serum (FBS) did not alter the gene transfer activity of Gal-α-CDE (G2, DSG4); 
however, this activity on the part of the dendrimer (G2), as well as that of α-CDE (G2, DSG2), 
Cyclodextrin - A Versatile Ingredient246
as pDNA vectors was decreased by the addition of FBS. Additionally, after co-incubation 
of Gal-α-CDE (G2, DSG4), dendrimer (G2), or Gal-α-CDE (G2, DS2) pDNA complex with 
asialofetuin and galactose, only a slight decrease in gene-transfer activity was observed in 
HepG2 cells, with no competitive effects. Consequently, these latter results confirmed that 
the mechanism associated with the enhanced gene-transfer activity of Gal-α-CDE (G2, DSG4) 
was not ASGPR-specific, but rather possibly due to other factors, such as increased stabil-
ity of the pDNA complex or changes in intracellular trafficking. Collectively, these results 
suggested that Gal-α-CDE (G2, DSG4) exhibited enhanced pDNA-transport activity along 
with low cytotoxicity and considerable resistance to serum-associated degradation and could, 
therefore, represent an excellent non-viral gene-delivery carrier.
2.4.2. Lactosylated α-CDEs as hepatocyte-selective pDNA and siRNA carriers
As previously mentioned, Gal-α-CDE (G2, DSG4) did not exhibit hepatocyte-specific gene-
delivery activity. Therefore, Arima et al. prepared lactose-appended α-CDEs (Lac-α-CDEs) 
containing a glucose moiety as a spacer between the dendrimer and the lactose moiety [62, 63]. 
Of the various Lac-α-CDEs (G2) harboring different degrees of substitution of lactose (DSLs; 
1.2, 2.6, 4.6, 6.2, and 10.2), Lac-α-CDE (G2, DSL2.6) exhibited the highest gene-transfer activity 
in HepG2 cells along with negligible cytotoxicity. To verify whether Lac-α-CDE (G2, DSL 2.6) 
could bind to galactose-binding lectins, the association constant of Lac-α-CDE (G2, DSL2.6) 
with peanut lectin was determined and compared with that of α-CDE (G2, DS2) using sur-
face plasmon resonance. The results showed that the association constant of Lac-α-CDE (G2, 
DSL2.6) was 100-fold greater than that of α-CDE (G2, DS2). It was previously reported that the 
dissociation constant of asialofetuin for ASGPR located on HepG2 cells is ~3.61 × 10−9 M [64]. 
These results indicated that the specific galactose-binding ability of Lac-α-CDE (G2, DSL2.6) 
was maintained, although the magnitude was not as strong as that of asialofetuin. To confirm 
the ASGPR-mediated gene-transfer activity of Lac-α-CDE (G2, DSL2.6), the effects of asialofe-
tuin, as a competitor on this activity, was examined in HepG2 cells. The results revealed that 
the gene-transfer activity of Lac-α-CDE (G2, DSL2.6) was significantly suppressed by asialofe-
tuin, and that cellular association of the Lac-α-CDE (G2, DSL2.6)/Alexa-pDNA complex was 
markedly reduced in the presence of asialofetuin. However, no inhibitory effect of asialofetuin 
was observed on the activity of α-CDE (G2, DS2)/Alexa-pDNA in HepG2 cells. These results 
indicated that the gene-transfer activity of Lac-α-CDE (G2, DSL2.6) was mediated by ASGPR 
endocytosis. Arima et al. then evaluated the ability of Lac-α-CDE (G2, DSL2.6) to deliver pDNA 
in vivo using the pGL3 luciferase system in mice. The complexes were intravenously injected 
into mice, and after 12 h, luciferase activity was determined. They observed that luciferase 
activity in the Lac-α-CDE (G2, DSL2.6) system was significantly higher than that observed in 
the α-CDE (G2) system in the liver. Furthermore, to estimate the safety profile of Lac-α-CDE 
(G2, DSL2.6), the effect of its pDNA complex on blood-chemistry data, such as CRE, BUN, AST, 
ALT, and LDH concentrations, was analyzed following intravenous administration to mice. The 
ALT concentration in the Lac-α-CDE (G2, DSL2.6) system, as well as in the jetPEI-hepatocyte 
system, was slightly elevated (no significant difference) as compared with that observed in the 
control. By contrast, all other parameters in the Lac-α-CDE (G2, DSL2.6) system were almost 
equivalent to those of controls. These results strongly suggested that Lac-α-CDE (G2, DSL2.6) 
exhibited hepatocyte-specific gene-transfer activity along with a good safety profile in vivo.
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Figure 2. PEG-LαC (G3) as a targeting carrier for siTTR delivery to hepatocytes.
Recently, Hayashi et al. prepared a PEGylated Lac-α-CDE [PEG-LαC (G3)] to improve in vivo 
gene-transfer activity by enhancing complex stability, as well as prolonging the half-life in 
circulation [62]. Of the various PEG-LαCs (G3), those with degrees of substitution of the PEG 
moiety (DSPs) of 2.1 [PEG-LαC (G3, DSP2.1] showed higher luciferase gene-transfer activity 
than other PEG-LαCs (G3, DSP4.0 and DSP6.2) in HepG2 cells along with negligible cyto-
toxicity up to a charge ratio of 50. Additionally, its gene-transfer activity decreased in the 
presence of asialofetuin, whereas it retained significantly higher gene-transfer activity, even 
in the presence of 50% serum. Additionally, PEG-LαC (G3, DSP2.1) showed selective gene-
transfer activity into hepatic parenchymal cells rather than hepatic non-parenchymal cells 
in vivo. Furthermore, blood-chemistry values, such as CRE, BUN, AST, ALT, and LDH con-
centrations, following administration of the PEG-LαC (G3, DSP2.1)/pDNA complex system 
were almost equivalent with those in controls, suggesting that PEG-LαC (G3, DSP2.1) showed 
potential as a hepatocyte-selective gene carrier both in vitro and in vivo.
The potential of PEG-LαC (G3) as a siRNA carrier was also evaluated (unpublished data), 
with an siRNA against transthyretin (TTR) mRNA (siTTR) used to treat TTR-related familial 
amyloidotic polyneuropathy (TTR-FAP). The results indicated that the PEG-LαC (G3)/siTTR 
complex significantly reduced TTR mRNA expression in the liver as compared with the Lac-
α-CDE (G3)/siTTR complex, suggesting the potential use of PEG-LαC (G3) as a hepatocyte-
selective siRNA carrier (Figure 2).
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2.4.3. Mannose and fucose-appended α-CDEs as Kupffer cell (KC)-selective pDNA and siRNA 
carriers
KCs are reticuloendothelial cells that reside within the lumen of the liver sinusoid and adhere 
to endothelial cells that form blood-vessel walls. These non-parenchymal cells represent ~15% 
of the total liver cells in the human body [65] and are the first macrophages that come into 
contact with bacteria and bacterial toxins derived from the gastrointestinal tract [66]. KCs 
also play a critical role in removing harmful materials circulating in the blood. Moreover, 
KCs are considered an essential part of innate immunity and play an important role in the 
rapid response to threatening stimuli. They are also involved in the pathogenesis of differ-
ent liver diseases, including viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver, 
development of liver fibrosis, and portal hypertension [67]. Importantly, KCs express ManR 
and FucR; therefore, both fucose and mannose can be used as targeting ligands on KCs used 
for nucleic acid delivery [68].
Arima et al. prepared mannose-appended α-CDEs (Man-α-CDE, G2) [39] to develop ManR-
targeted non-viral carriers by attaching mannose residues to primary amino acid residues of 
α-CDE (G2) using an α-D-mannopyranosylphenyl isothiocyanate spacer. Of the various Man-
α-CDEs (G2) with degrees of substitution of mannose (DSMs) of 1.1, 3.3, 4.9, and 8.3, Man-α-
CDEs (G2, DSM3.3 and DSM4.9) showed higher gene-transfer activity as compared with that 
of dendrimer (G2) and α-CDE (G2) in NR8383 cells, a rat lung macrophage cell line, with no 
cytotoxicity observed up to charge ratio of 200 (carrier/pDNA). However, Man-α-CDE (G2) 
also showed high gene-transfer activity in A549 cells [ManR (−)], suggesting its low selectivity 
for ManR, possibly due to the rigidity of the spacer.
More recently, Arima et al. prepared a new Man-α-CDE with a α-D-mannopyranosylprop
ylthiopropionylated α-CDE (G3) spacer [Man-S-α-CDEs (G3)], which was longer and more 
flexible than that in Man-α-CDE [69, 70]. In this study, nuclear factor (NF)-κB was targeted 
due to its important role in the inflammatory response, and because it is found in almost all 
animal cell types. Therefore, to suppress NF-κB activation, NF-κB siRNA and NF-κB-decoy 
DNA were employed, with both strategies potentially attractive for the treatment of cytokine-
related liver diseases, such as fulminant hepatitis. Of the various Man-S-α-CDEs with differ-
ent DSMs, the NF-κB p65-specific siRNA (sip65) complex with Man-S-α-CDE (G3, DSM4) 
showed significantly lower NF-κB p65 mRNA levels and nitric oxide levels in lipopolysac-
charide (LPS)-stimulated NR8383 cells following ManR-mediated endocytosis (Figure 3). 
Intravenous administration of the Man-S-α-CDE (G3, DSM4)/sip65 complex increased the 
survival rate of the LPS-induced fulminant hepatitis mouse model via significant in vivo RNAi 
activity. These results suggested that Man-S-α-CDE (G3, DSM4) represented a potential novel 
KC-selective siRNA carrier.
Several reports demonstrated that NF-κB-decoy complexes harboring a liposome-function-
alized fucose moiety showed higher gene-transfer efficiency as compared with mannose-
appended liposomes specific for KCs [71, 72]. Therefore, Akao et al. prepared thioalkylated 
fucose-appended α-CDEs [Fuc-S-α-CDE (G2)] and assessed their potential as KC-selective 
carriers of decoy DNA (Figure 4) [73]. The NF-κB-decoy in complex with Fuc-S-α-CDE (G2) 
with an average degree of substitution of fucose (DSFuc) of two suppressed the production of 
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nitric oxide, as well as tumor necrosis factor-α (TNF-α) expression, in LPS-simulated NR8383 
cells through FucR-mediated cellular uptake and successful endosomal escape. This complex 
also improved survival rates following intravenous injection into a fulminant hepatitis mouse 
model. Moreover, Fuc-S-α-CDE (G2, DSFuc2)/NF-κB decoy complexes showed marked accu-
mulation in the liver relative to that observed in other organs. Furthermore, serum ALT and 
AST levels, as well as TNF-α levels, significantly decreased after intravenous administration 
of the complex in mice with fulminant hepatitis. These results suggested the potential of the 
Fuc-S-α-CDE (G2)/NF-κB decoy complex as an oligonucleotide therapy for fulminant hepati-
tis. There are many other receptors available for KC-specific drug targeting, including galac-
tose receptors, scavenger receptors, CD36, lol-density lipoprotein receptor, and complement 
receptors [74]; therefore, future studies on the utility of fucose in this context should focus on 
its efficacy with different ligands.
Figure 3. Man-S-α-CDE (G3) as a KC-specific targeting carrier via ManR.
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2.4.4. Folate PEG-appended α-CDEs as cancer-cell-selective pDNA and siRNA carriers
To achieve maximum effective therapeutic effects against cancer using siRNAs, the design 
of tumor-selective delivery systems is extremely crucial. Folic acid has often been used as 
a tumor-specific ligand [75, 76], because it is relatively affordable as compared with other 
cancer-targeting ligands and is capable of high-affinity interactions with the FR-α receptor 
Figure 4. Fuc-S-α-CDE (G2) as targeting decoy DNA carrier to KCs.
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expressed on the surface of many cancer cells (k
d
 > 10−9–10−10 M). FR-α is highly expressed in 
several tumor cells, including those associated with lung, ovary, breast, kidney, and brain 
cancers, and is negligibly expressed in normal tissues. Additionally, as the cancer progresses 
in stage, the FR-α expression increases substantially. Therefore, folic acid is considered an 
ideal candidate cancer-cell-selective ligand.
Arima et al. prepared a folic acid-appended α-CDE (G3) with a PEG spacer [Fol-PαC (G3)] 
to fabricate a cancer-selective gene and siRNA carrier. Fol-PαC (G3) showed selective FR-α-
overexpressing tumor-cell gene-transfer activity [77]. Specifically, Fol-PαC (G3) with an aver-
age degree of substitution of folate (DSF) of five showed significantly higher gene-transfer 
activity as compared with that of α-CDE (G3) in KB cells [FR-α (+)], but not in A549 [FR-α (−)] 
cells along with negligible cytotoxicity. Moreover, Fol-PαC (G3, DSF5) showed higher gene-
transfer activity than α-CDE (G3) after intratumoral injection in mice bearing tumors.
The potential of Fol-PαC (G3) for delivery of siRNA to FR-α-overexpressing cancer cells was 
evaluated [78], showing that Fol-PαC (G3, DSF4) exhibited high siRNA-transfer activity in 
KB cells [FR-α (+)] in the absence of cytotoxicity up to a charge ratio of 100 (carrier/siRNA). 
Notably, the Fol-PαC (G3, DSF4)/siRNA complex showed significant RNAi activity following 
intratumoral injection; however, this was not the result of its dissociation in blood.
Ohyama et al. then prepared Fol-PαCs using a higher-generation dendrimer (G4) and evalu-
ated their potential as tumor-targeting siRNA carriers in vitro and in vivo [79]. The Fol-PαC 
(G4, DSF2)/siRNA complex showed prominent RNAi activity based on adequate physico-
chemical properties, FR-α-mediated endocytosis, efficient endosomal escape, and siRNA 
delivery to the cytoplasm along with negligible cytotoxicity (Figure 5). Most importantly, Fol-
PαC (G4, DSF2) showed improved siRNA-specific blood-circulating ability, serum stability, 
and in vivo RNAi activity as compared with those observed with Fol-PαC (G3). Additionally, 
Fol-PαC (G4, DSF2) in complex with siRNA against Polo-like kinase 1 (siPLK1) suppressed 
tumor growth as compared with that observed using a control siRNA complex in mice bear-
ing colon-26 tumor cells. These results suggested that Fol-PαC (G4) represented a potential 
novel tumor-targeting siRNA carrier in vitro and in vivo.
2.5. 6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl (GUG)-β-CDE as a pDNA and siRNA 
carrier
Arima et al. clarified the importance of a spacer between the dendrimers and the targeting ligands 
for providing cell-specific pDNA delivery [78, 80]. However, the effect of a spacer between 
the CyD and the dendrimer on the gene-transfer activity of the CDE remained unknown. 
Consequently, a new CDE was prepared (GUG-β-CDE) utilizing a glucuronyl-glucosyl group 
as a spacer between the CyD and the dendrimer. Additionally, GUG-β-CyD has many advan-
tages over the parent β-CyD, including higher water solubility, lower hemolytic activity, and 
increased bioadaptability [81]. Moreover, it contains a carboxyl group capable of interacting with 
primary amino groups present in dendrimers. Of the various GUG-β-CDEs (G2) having differ-
ent DS values, GUG-β-CDE (G2, DS1.8) showed higher gene-transfer activity in vitro as com-
pared with other GUG-β-CDEs (DS1.2, DS2.5, and DS4.5) [82]. Additionally, GUG-β-CDE (G2, 
DS1.8) showed higher gene-transfer activity relative to that of α-CDE (G2, DS1.2) and β-CDE 
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(G2, DS1.3) in A549 cells and RAW264.7 cells, respectively, possibly due to the pDNA complex 
exhibiting an increased ability to escape endosomes and a high degree of nuclear localization [39, 
83, 84]. Moreover, in vivo GUG-β-CDE (G2, DS1.8) gene-transfer activity was much higher than 
that of α-CDE (G2, DS1.2) or β-CDE (G2, DS1.3) in kidney at 12 h after intravenous injection of the 
complexes in mice [85]. Therefore, GUG-β-CDE (DS1.8) might have potential as a pDNA carrier 
for gene-transfer targeting the kidney. Furthermore, no cytotoxicity was observed in A549 cells 
or RAW264.7 cells up to a charge ratio of 200 (carrier/pDNA). The hemolytic activity of GUG-
β-CDE (G2, DS1.8) in rabbit red blood cells was also substantially lower than that associated 
with the dendrimer, and negligible changes in the blood-chemistry data were observed 12 h after 
Figure 5. Fol-PαC (G4) as a targeting-siRNA carrier to folate-expressing tumor cells.
Promising Use of Cyclodextrin-Based Non-Viral Vectors for Gene and Oligonucleotide Drugs
http://dx.doi.org/10.5772/intechopen.74614
253
intravenous administration of the GUG-β-CDE (G2, DS1.8)/pDNA complex in mice. These results 
strongly suggested that this complex showed a good safety profile in vivo and in vitro, and that it 
might constitute an adequate carrier for gene therapy targeting kidney diseases, such as polycys-
tic kidney disease, Alport syndrome, renal cancers, glomerulonephritis, and renal fibrosis.
Additionally, Anno et al. evaluated the potential of GUG-β-CDE (G2) as a siRNA carrier. GUG-β-
CDE (G2, DS1.8) in complex with siTTR showed high RNAi activity with no cytotoxicity in HepG2 
cells. Moreover, TTR mRNA-expression levels were reduced after intravenous administration of 
the complex to BALB/c mice, with only minor changes in blood-chemistry parameters, suggesting 
the potential of GUG-β-CDE (G2, DS1.8) as a siRNA carrier for the treatment of TTR-FAP [86].
Moreover, Ahmed et al. prepared a GUG-β-CDE using a higher-generation dendrimer (G3) 
[87]. Various GUG-β-CDEs (G3, DS1.6, DS3.0, DS3.7, DS5.0, and DS8.6) were prepared, with 
the GUG-β-CDE (G3, DS3.7)/siRNA complex showing the highest RNAi activity in KB cells 
transiently expressing the luciferase gene and colon 26-luc cells stably expressing the lucif-
erase gene. Moreover, the GUG-β-CDE (G3, DS3.7)/FITC-siRNA complex showed the high-
est cellular uptake along with negligible cytotoxicity at a charge ratio of 20 (carrier/siRNA). 
Additionally, cellular uptake of the GUG-β-CDE (G3, DS3.7)/FITC-siRNA complex was sig-
nificantly higher than that of the α-CDE (G3, DS2.4)/FITC-siRNA complex, suggesting GUG-
β-CDE (G3, DS3.7) as a potential effective siRNA carrier. Currently, folate-PEG-appended 
GUG-β-CDEs (G3) are in development as a cancer-selective GUG-β-CDE (G3) variant.
2.6. Conclusion
In this review, we described various CDEs used as gene and oligonucleotide carriers. These 
multifunctional CDEs showed great potential as carriers for DNA and nucleic acid drugs. 
The advantages of these CDEs included (1) low cytotoxicity; (2) facile modification of various 
targeting ligands and polymers, such as PEG; and (3) enhanced endosomal-escape ability via 
the synergistic action of the proton-sponge effect in the dendrimer and the interaction of CyD 
with membrane lipids. Therefore, these CyD-based carriers have the potential for utilization 
as multifunctional carriers for pDNA, siRNA, decoy DNA, and shRNA.
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